Frontotemporal dementia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TDP-43 4
• C9orf72 0
• MAPT 1
• TREM2 0
• CSF1R 0
• SOD1 0
• NRF2 0
• AKT 0
• APOE 0
• CDK4/6 0
• GLP-1 0
• HMGB1 0
• LRRK2 0
• MAPK 0
• SIRT1 0
• SNCA 0
• STING 0
• TP53 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

  NCT05978804· Johns Hopkins University· Updated 21 Oct 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Nabilone for Agitation in Frontotemporal Dementia

  NCT05742698· Simon Ducharme, MD· Updated 28 Jul 2026

  “Terminated due to slow recruitment: only 3 randomized in 2 years. Eligible population overestimated and funding exhausted; PI deemed further recruitment unfeasible. No participants on treatment, no safety concerns. All sites are now closed.”Registry text, quoted unchanged. Source

• Terminated

  Circuitry Assessment and Reinforcement Training Effects on Recovery

  NCT04290988· Johns Hopkins University· Updated 5 Feb 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Continuation Study for Latozinemab

  NCT06111014· Alector Inc.· Updated 21 Jan 2026

  “The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's”Registry text, quoted unchanged. Source

• Withdrawn

  Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia

  NCT04486586· Johns Hopkins University· Updated 24 Apr 2025

  “The study was withdrawn due to a shift in research priorities, with the decision made to focus resources on other studies that align more closely with the current strategic goals.”Registry text, quoted unchanged. Source

• Withdrawn

  Predict to Prevent PGRN Disease

  NCT06711510· Assistance Publique - Hôpitaux de Paris· Updated 21 Mar 2025

  “loss of funding”Registry text, quoted unchanged. Source

• Withdrawn

  Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

  NCT01459302· University of Massachusetts, Worcester· Updated 19 Sept 2024

  “This study is not a clinical trial.”Registry text, quoted unchanged. Source

• Withdrawn

  Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS

  NCT05830214· University of Alberta· Updated 8 Feb 2024

  “Difficulty procuring study device”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia

  NCT05497817· Mayo Clinic· Updated 17 Nov 2022

  “Study withdrawn and being modified under another protocol”Registry text, quoted unchanged. Source

• Withdrawn

  tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study

  NCT04883229· University of California, San Francisco· Updated 19 Aug 2022

  “The tDCS device that was going to be used for this study is no longer being made.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies

  NCT07868328· Novartis Pharmaceuticals· Source

• ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

  NCT04363684· Mayo Clinic· Source

• Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases

  NCT05326750· Kuopio University Hospital· Source

• Alzheimer's Disease Neuroimaging Initiative 4

  NCT05617014· University of Southern California· Source

• A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.

  NCT06823752· Woolcock Institute of Medical Research· Source

• Remotely-supervised Neuromodulation in PPA

  NCT07260253· Maya Henry· Source

• Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

  NCT06856850· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source

• Longitudinal Early-onset Alzheimer's Disease Study Protocol

  NCT03507257· Indiana University· Source

• Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

  NCT05331144· Rong Zhang· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Organoids 4
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 1
• Gene Expression Profiling 4
• Whole Genome Sequencing 3
• Exome Sequencing 1
• Proteomics 16
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 2
• Immunohistochemistry 1
• Positron-Emission Tomography 28
• Magnetic Resonance Imaging 73
• Machine Learning 18
• Deep Learning 9
• Cohort Studies 34
• Genome-Wide Association Study 13

• Differentiating behavioural variant frontotemporal dementia from misdiagnoses by deriving atrophy through deep-learning-based CT to MRI synthesis: A proof-of-concept study.

  Eur J Radiol, Jul 2026

• Deep Model Families for EEG-Based Multi-Class Dementia Classification.

  Int J Neural Syst, Jul 2026

• Design and Development of an Automated Electroencephalogram Signal Processing and Diagnostic Support Architecture Employing Advanced Deep Learning Models for Early Accurate and Scalable Detection of Neurological Diseases.

  Physiother Res Int, Apr 2026

• Deep learning-based synthetic brain MRI for the assessment of regional atrophy patterns in neurodegenerative diseases.

  Eur Radiol, Feb 2026

• A new graph-transformer framework for EEG-based differentiation of Alzheimer's disease and frontotemporal dementia.

  Biomed Phys Eng Express, Feb 2026

• Deep neural networks and genome-wide associations reveal the polygenic architecture of local brain aging.

  Geroscience, Dec 2025

• Computed tomography-based nnU-Net for region-specific brain structural changes across the alzheimer's continuum and frontotemporal dementia subtypes.

  Sci Rep, Nov 2025

• A novel approach integrating topological deep learning from EEG Data in Alzheimer's disease.

  Sci Rep, Nov 2025

• Time-Frequency Analysis of Frontal EEG Channels for Alzheimer's Disease Detection Using Deep Learning.

  Annu Int Conf IEEE Eng Med Biol Soc, Jul 2025

See which targets of this disease your abstract mentions, and go to the people working on them.